UNC to Receive $26.9M from DARPA to Develop Psychiatric Medicines
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
Industry
CaaMTech Partners with the National Institutes of Health to Study Synthetic Tryptamines
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
Stopping Bad LSD Trips with “Off-Switch” Technology
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
UK Assessment Agency Rejects Spravato Ketamine Nasal Spray
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
COMPASS Patent Highlights Importance of Crystallography in Psychedelic Drug Development
The scope and validity of this patent will depend on how x-ray diffraction data is interpreted.
Machine Intervention: Psychedelics, Artificial Intelligence, and the Drug Discovery Process
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare
Silo Wellness Announces Magic Mushroom Microdosing Nasal Spray
Nasal spray formulations could offer precision dosing of a spectrum of psychedelic mushroom compounds to consumers.
Regulatory Hurdles Facing Psychedelics
Market introduction of psychedelics as a therapy looks promising. However, policy and regulatory issues concerning the drug class still exist.
Scientists Engineer E. Coli to Produce Psilocybin
This is the first time psilocybin has been produced from a prokaryotic organism.
Exploring the Potential Recreational Psilocybin Market
Scientific and public opinion is slowly shifting for the potential usage of psilocybin in a variety of conditions. Can the same be said for recreational usage?